InSilicoTrials Company Research Report

Company Overview

Name

InSilicoTrials Technologies

Mission of the Company

To revolutionize drug development by harnessing the power of in silico technology. The company aims to boost the world’s transition to accessible therapies.

Founded and Founders

No information is available.

Key People in the Company

• Luca Emili - Founder and CEO

• Mario Torchia - Chief Operating Officer

• Alessandro Collesano - Chief Financial Officer

• Daniel Röshammar - VP of Research & Development

• Pauline Bambury - Pharmacometrician

• Alessia Baretta - Sr. Product Manager MedTech

• Matteo Libero Baroni - Business Development

• Marc Antonio Bisotti - Software Engineer

• Giacomo Brunetta - Software Engineer

• Vincenzo Carbone - Sr. Product Manager MedTech

• Chiara Dorigo - Executive Assistant

• Michael Eckstut - Senior Advisor

• Matteo Gazzin - Engineering Manager

• Nataša Mandić - Content Strategist

• Walter Marchi - Corporate Business Development Manager

• Manasa Parthasharathy - Business Development Manager

• Giuseppe Pasculli - Pharmacometrician

• Emanuele Pertosi - Administration Officer

• Francesco Speciale - Junior Data Scientist

• Fianne Sips - Pharmacometrician

• Sofia Stathopoulos - VP Business Development

• Nathan Teuscher - Consultant

• Niccolò Totis - Pharmacometrician

• Davide Turrini - Software Engineer

• Valerio Valente - Junior Data Scientist

• Marco Virgolini - Head of Artificial Intelligence

Headquarters

No information is available.

Number of Employees

The company represents 16 employees from 6 different nationalities.

Revenue

No information is available.

What is the Company Known For

InSilicoTrials is known for providing computational models and AI technologies to accelerate drug research and development processes. Their solutions aim to reduce reliance on traditional methods such as animal testing and extensive clinical trials, thereby improving the safety of medical products and significantly cutting R&D costs.

Products and Services

Products Offered

InSilicoTrials offers a comprehensive suite of modeling and simulation tools tailored for various stages of drug and medical device development. Their products include:

1. Drug Repurposing (InSilicoDISCOVERY Suite)

• Predicts biological targets and corresponding bioactivity of compounds.

2. Molecular Docking (InSilicoDISCOVERY Suite)

• Explores target-ligand interactions and binding affinities.

3. Macrophages Polarization

• Simulates phenotype changes during polarization experiments.

4. QT/TdP Risk Screen (InSilicoCARDIO Suite)

• Predicts proarrhythmic risk using machine learning.

5. MS TreatSim (InSilicoNEURO)

• Generates in silico trials and therapeutic predictions.

6. PCa GnRH Agonists Simulator (InSilicoONCO Suite)

• Simulates clinical trials for prostate cancer treatments.

7. XPS (CMC)

• Simulates pharmaceutical fluid-granular processes to improve product quality.

8. In Silico Microbiome

• Predicts microbiome-based therapy indications.

High Level Description of the Products

InSilicoTrials provides software solutions to predict drug interactions, simulate clinical trials, evaluate drug safety and efficacy, and enhance the design and function of medical devices. Their platform facilitates digital transformation in R&D via modeling and simulation, leveraging artificial intelligence for better decision-making.

Key Features of Each Product

• Drug Repurposing: Utilizes large databases to enhance drug discovery.

• Molecular Docking: Assesses molecular interactions and binding strength.

• Macrophages Polarization: Customizable conditions for in vitro studies.

• QT/TdP Risk Screen: Machine learning approach for cardiac safety evaluation.

• MS TreatSim: Personalized effect predictions for multiple sclerosis.

• PCa GnRH Agonists Simulator: Adaptive simulations for prostate cancer therapies.

• XPS: Efficacious solution for analyzing and improving fluid dynamics in production processes.

• In Silico Microbiome: Data-driven insights for microbial therapeutic applications.

Recent Developments

Recent Developments in the Company

• InSilicoTrials was highlighted in the HSBC Venture Healthcare Report for 1H 2024.

• Awarded the 2023 Innovation Radar Prize in AI and Smart Devices category.

• Partnership with AVL to extend simulation offerings.

New Products Launched

• Two new state-of-the-art simulation tools for oncology released in October 2021.

New Features Added to Existing Products

No information is available.

New Partnerships

• Collaboration with RCPE to optimize pharmaceutical processes.

• Partnership with DSTC to enhance ion channel assay capabilities.

• Joint initiative with AchilleS Vaccines to develop next-gen vaccines and monoclonal antibodies.

• Collaboration with Premier Research to facilitate rare disease therapies.

This detailed report reflects on available data and will allow stakeholders to better understand the strategic orientation, product offerings, and potential collaborations of InSilicoTrials in their market activities.